RX Review: Advancing Bladder Cancer Care: Exploring Subcutaneous Immunotherapy

This segment outlines how immune checkpoint inhibitors have become essential in bladder cancer management, examining their roles across treatment lines and the current standards of care.

This discussion compares subcutaneous and intravenous immunotherapy delivery, highlighting differences in clinical use, patient convenience, and overall treatment experience.

The segment reviews clinical trial outcomes and real-world findings on subcutaneous immunotherapy, focusing on efficacy, safety, and its practical application in daily urology practice.

This section explores how subcutaneous delivery can improve patient satisfaction, adherence, and quality of life through reduced treatment times and greater convenience.

The final segment discusses operational and logistical impacts, including workflow efficiency, staff training, and reimbursement considerations for subcutaneous immunotherapy.